BSP Medical

Medical Devices, Healthcare IT
Diagnostic & Monitoring
Therapeutic Area(s):
Company Status:
Revenue Growth

HyperQ technology detects stress induced and acute resting ischemic heart disease IHD in High-Frequency ECG signals, meeting the need of a low-cost and reliable cardiac testing tools.

The powerful prediction and analysis tools of HyperQ accurately diagnose and alerts on critical cardiac conditions. Enables Big Data analysis of ECG records and also integrates into cloud based wearable wireless home care applications.

HyperQ is a proprietary and patented technology. It analyses the high-frequency ECG QRS Depolarization segment of the cardiac cycle. Conventional ECG analysis of the ST segment is related to the Repolarization. HyperQ provides superior sensitivity and accurate results.

The HyperQ™ revolutionizes the field of diagnosing coronary artery disease (CAD) diagnosis, preventing unnecessary exposure to radioactive or invasive procedures associated with advanced IHD diagnosis systems. HyperQ sensitivity and specificity are similar to those of radioactive procedures, performing equally well in men and women, thus allowing for a dramatically enhanced diagnosis in women.

Accurate diagnosis by the HyperQ™ saves the time and cost of other further, expensive IHD tests.

To date, thousands of patients were diagnosed by the HyperQ in controlled clinical studies, in hospitals and private physician offices. The clinical results are published in leading cardiology journals.

The American Heart Association (AHA) included HyperQ in its last statement on exercise standards for testing (published in August 2013), pointing out that it has been found to have useful test performance for detection of CAD.

The HyperQ received FDA clearance and CE marking.